Foster & Motley Inc. Has $2.38 Million Holdings in Bristol Myers Squibb Company $BMY

Key Points

• Foster & Motley Inc. increased its holdings in Bristol Myers Squibb Company by 34.7%, bringing their total investment to $2.38 million with 51,493 shares.
• Institutional investors currently own 76.41% of Bristol Myers Squibb stock, indicating strong interest in the company.
• Bristol Myers Squibb recently announced a quarterly dividend of $0.62 per share, with an annual yield of 5.7%.

Foster & Motley Inc. boosted its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 34.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,493 shares of the biopharmaceutical company's stock after buying an additional 13,268 shares during the quarter. Foster & Motley Inc.'s holdings in Bristol Myers Squibb were worth $2,384,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. New England Asset Management Inc. grew its stake in Bristol Myers Squibb by 0.8% in the 1st quarter. New England Asset Management Inc. now owns 39,476 shares of the biopharmaceutical company's stock valued at $2,408,000 after buying an additional 305 shares during the last quarter. Commonwealth Equity Services LLC grew its position in Bristol Myers Squibb by 1.1% in the 1st quarter. Commonwealth Equity Services LLC now owns 1,288,407 shares of the biopharmaceutical company's stock worth $78,580,000 after purchasing an additional 13,959 shares during the last quarter. Sage Capital Advisors llc grew its position in Bristol Myers Squibb by 60.7% in the 2nd quarter. Sage Capital Advisors llc now owns 85,234 shares of the biopharmaceutical company's stock worth $3,946,000 after purchasing an additional 32,181 shares during the last quarter. Ransom Advisory Ltd acquired a new stake in Bristol Myers Squibb in the 1st quarter worth $843,000. Finally, Castle Rock Wealth Management LLC grew its position in Bristol Myers Squibb by 458.2% in the 2nd quarter. Castle Rock Wealth Management LLC now owns 44,559 shares of the biopharmaceutical company's stock worth $2,088,000 after purchasing an additional 36,576 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares of the company's stock, valued at $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.09% of the stock is owned by corporate insiders.

Analyst Ratings Changes

BMY has been the topic of several research analyst reports. Citigroup restated a "neutral" rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. Morgan Stanley restated a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Daiwa America lowered shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target on the stock. in a research report on Tuesday, August 5th. Finally, Weiss Ratings reiterated a "hold (c-)" rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fourteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of "Hold" and an average target price of $57.23.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $43.63 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.96 and a twelve month high of $63.33. The firm has a market cap of $88.80 billion, a P/E ratio of 17.59, a price-to-earnings-growth ratio of 2.26 and a beta of 0.33. The firm's 50-day simple moving average is $46.07 and its 200-day simple moving average is $47.47. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. During the same period last year, the firm posted $2.07 EPS. The firm's quarterly revenue was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.7%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.